Alzheimer’s Diagnosis Enters a New Era: The Rise of Blood-Based Biomarkers
For decades, diagnosing Alzheimer’s disease has been a complex and often invasive process, relying on cognitive tests and expensive brain imaging. However, a significant shift is occurring. The emergence of blood-based biomarker tests is transforming how clinicians detect the disease, offering a noninvasive, cost-effective way to identify Alzheimer’s markers years before symptoms fully manifest.
- The FDA has cleared the first blood test to aid in diagnosing Alzheimer’s in symptomatic adults.
- Specific biomarkers, such as pTau217, can signal disease progression years before brain scans show changes.
- The Alzheimer’s Association has released its first official clinical practice guideline for using these tests.
- Blood tests provide a more accessible alternative to costly PET scans and invasive procedures.
The Breakthrough: FDA-Cleared Blood Testing
In May 2025, the U.S. Food and Drug Administration (FDA) cleared the first in vitro diagnostic device designed to aid in the diagnosis of Alzheimer’s disease. This test, known as the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio, is intended for adult patients aged 55 and older who are already exhibiting signs and symptoms of the disease.
The test works by measuring two specific proteins found in human plasma: pTau217 and β-amyloid 1-42. By calculating the numerical ratio of these two proteins, clinicians can better detect the presence of amyloid plaques, which are a hallmark sign of Alzheimer’s disease.
Detecting Alzheimer’s Before Symptoms Appear
While FDA clearance focuses on symptomatic patients, research indicates that blood tests may have an even broader application. A study published in Nature Communications suggests that measuring the biomarker pTau217 can reveal the earliest signs of disease progression in otherwise healthy older adults.
According to Medical News Today, higher levels of pTau217 in cognitively healthy adults are linked to a faster buildup of tau and amyloid proteins, as well as future cognitive decline. Crucially, these changes often occur years before symptoms appear or before the disease is detectable on traditional brain scans, making blood tests a potentially more sensitive tool for early detection.
Why This Matters: Moving Beyond PET Scans
Traditionally, doctors have used amyloid positron emission tomography (PET) scans to visualize plaques in the brain. While effective, PET scans come with significant drawbacks: they are costly, time-consuming, and expose patients to radiation.
Blood-based biomarkers offer several critical advantages:
- Accessibility: They provide an inexpensive and noninvasive alternative to imaging.
- Early Intervention: Timely diagnosis allows individuals to prioritize their health and may aid reduce cognitive and functional decline.
- Scalability: With an estimated 7 million American adults living with Alzheimer’s, these tests increase the opportunity for widespread early screening.
Standardizing Care: New Clinical Guidelines
As these tools become available, standardization is essential to ensure they are used safely, and effectively. To address this, the Alzheimer’s Association released its first clinical practice guideline on blood-based biomarker tests at AAIC 2025. This landmark step provides a framework for clinicians to integrate these tests into standard diagnostic workflows.
Frequently Asked Questions
Who can currently use these blood tests?
The FDA-cleared Lumipulse G test is specifically for adults aged 55 and older who are exhibiting signs and symptoms of Alzheimer’s disease.
Can a blood test replace a brain scan entirely?
Currently, these tests are used to aid in diagnosis. They provide critical data on amyloid plaques and tau proteins, but doctors typically combine these results with medical history, cognitive tests, and neurological exams to determine the cause of a patient’s symptoms.
What is pTau217?
pTau217 is a phosphorylated version of the tau protein. Elevated levels of this protein in the blood are associated with the buildup of amyloid and tau in the brain, signaling the progression of Alzheimer’s disease.
Looking Ahead
The integration of blood-based biomarkers marks a pivotal shift in neurology. By moving detection from the imaging suite to the blood draw, the medical community is opening the door to earlier diagnosis and more timely treatment. As guidelines evolve and technology improves, these tests will likely become a cornerstone of preventative brain health and geriatric care.
Worth a look